Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF
Bruno Chauffert(Centre Hospitalier Universitaire Amiens-Picardie), L. Feuvret(Sorbonne Université), Franck Bonnetain(Methodology and Quality of Life Unit in Oncology), Luc Taillandier, Didier Frappaz, H. Taillia(HIA du Val-de-Grâce à Paris), Roland Schött, Jérôme Honnorat(Lyon College), Michel Fabbro(League Against Cancer), Isabelle Tennevet(League Against Cancer), François Ghiringhelli(League Against Cancer), Jean Sébastien Guillamo(Université de Caen Normandie), Xavier Durando(League Against Cancer), D. Castéra(Clinique Saint Pierre), M. Frénay(League Against Cancer), C. Campello(Université de Nîmes), Cécile Dalban(League Against Cancer), J. Skrzypski(League Against Cancer), Olivier Chinot(Hôpital de la Timone)
Cited by 96Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis